Investigation on the Middle Size Molecule Elimination Characteristics of the FXCorDiax 100 in Relation to the FX 100 and the Polyflux 210 H Dialyser
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Aarau, Switzerland, CH-5001
- Nephrology Division, Kantonsspital Aarau
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- hemodialysis patients 18 years and older
- treated by post dilution on-line Hemodiafiltration (HDF) for at least one month
- who reached a dialysis dose (Kt/V) of at least 1.2 at each of the last two monthly checks
- who are on a stable anticoagulation and anemia management
- whose hemoglobin is between 10.5 and 13.0 g/dl
- who are clinically stable based on judgment of nephrologist
- who are on a regular thrice weekly HDF schedule, e.g. Monday-Wednesday-Friday or Tuesday-Thursday-Saturday,
- who have a good vascular access (fistula or graft) which enables easy insertion of the needles and suitable effective blood flow (> 300 ml/min)
- who are able to understand the nature and requirements of the clinical investigation and who have given written informed consent
Exclusion Criteria: Patients
- with active Hepatitis B, Hepatitis C or HIV infection
- who are severely malnourished as judged by the principal investigator
- who are known or suspected to have allergy to the trial products or related products
- with a central venous catheter based vascular access
- who are abusing non-legal drugs or alcohol
- who have currently active malignant disease
- who are female of child-bearing age without effective measures of contraception, pregnant or breastfeeding
- who participate simultaneously in another clinical investigation
- who have participated in othe clinical investigations during the last month
- who are uncooperative
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: FX 100 dialyzer
|
4 h online hemodiafiltration with measurement of clearance and removal rate by split dialysate collection and bloodside measurements
|
|
Other: Polyflux 210 H dialyzer
|
4 h online hemodiafiltration with measurement of clearance and removal rate by split dialysate collection and bloodside measurements
|
|
Other: FXCorDiax 100 dialyzer
|
4 h online hemodiafiltration with measurement of clearance and removal rate by split dialysate collection and bloodside measurements
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clearance and removal rate of phosphate, beta2 microglobulin and leptin
Time Frame: 4 hour
|
during a 4 hour online hemodiafiltration session
|
4 hour
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Andreas Bock, MD, Nephrology Division, Kantonsspital Aarau
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HD-FX-01-CH
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.